NZ535531A - Compound and use in treatment - Google Patents

Compound and use in treatment

Info

Publication number
NZ535531A
NZ535531A NZ535531A NZ53553104A NZ535531A NZ 535531 A NZ535531 A NZ 535531A NZ 535531 A NZ535531 A NZ 535531A NZ 53553104 A NZ53553104 A NZ 53553104A NZ 535531 A NZ535531 A NZ 535531A
Authority
NZ
New Zealand
Prior art keywords
bph
preservatives
compound
alpha
treatment
Prior art date
Application number
NZ535531A
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of NZ535531A publication Critical patent/NZ535531A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is the use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (Compound A) either by itself, with a second BPH active agent, or dissolved in fractionated coconut oil with preservatives, in the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH), where in: The second BPH active agent is an alpha-adrenergic receptor blocking agent such as terazosin, doxazosin, tamsulosin, silodosin, AIO-8507L or RBx-2258 The fractionated coconut oil is Miglyol 812 and the preservatives are selected from butylated hydroxytoluene, butylated hydroxyanisole and mixtures thereof.
NZ535531A 2003-09-24 2004-09-23 Compound and use in treatment NZ535531A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
NZ535531A true NZ535531A (en) 2006-03-31

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535531A NZ535531A (en) 2003-09-24 2004-09-23 Compound and use in treatment

Country Status (12)

Country Link
EP (1) EP1673096A1 (en)
JP (2) JP2007506699A (en)
CN (1) CN100488511C (en)
BE (1) BE1016292A3 (en)
BR (1) BRPI0404050A (en)
CH (1) CH698144B1 (en)
EA (1) EA010240B1 (en)
FR (1) FR2859910B1 (en)
HK (1) HK1085373A1 (en)
NL (1) NL1027109C2 (en)
NZ (1) NZ535531A (en)
WO (1) WO2005027923A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1800677A4 (en) * 2004-10-05 2008-04-02 Kissei Pharmaceutical Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
JPWO2006038619A1 (en) * 2004-10-06 2008-05-15 キッセイ薬品工業株式会社 Pharmaceutical composition for preventing transition to surgical therapy for benign prostatic hyperplasia
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (en) * 2017-03-20 2018-09-21 Pierre Fabre Medicament USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
CA2289209C (en) * 1997-05-16 2006-07-25 Women & Infants Hospital Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds

Also Published As

Publication number Publication date
NL1027109A1 (en) 2005-03-29
WO2005027923A1 (en) 2005-03-31
CH698144B1 (en) 2009-05-29
EA010240B1 (en) 2008-06-30
JP2009035559A (en) 2009-02-19
NL1027109C2 (en) 2005-05-03
FR2859910B1 (en) 2006-04-28
CN100488511C (en) 2009-05-20
FR2859910A1 (en) 2005-03-25
EP1673096A1 (en) 2006-06-28
BE1016292A3 (en) 2006-07-04
HK1085373A1 (en) 2006-08-25
BRPI0404050A (en) 2005-06-14
CN1615891A (en) 2005-05-18
EA200401100A1 (en) 2005-04-28
JP2007506699A (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
ATE518540T1 (en) NEUROTHERAPEUTIC COMPOSITION CONTAINING BETA-LACTAM COMPOUND
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
HRP20050510A2 (en) Microbicide substances
ATE427747T1 (en) PHARMACEUTICAL FORMS CONTAINING A PROTON PUMP INHIBITOR, AN NSAID AND A BUFFER
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
ATE538103T1 (en) QUINAZOLINONE COMPOUNDS AS ANTICANCER AGENTS
AR032643A1 (en) COMBINATIONS OF STEROL ABSORPTION INHIBITOR (S) WITH CARDIOVASCULAR AGENT (S) FOR THE TREATMENT OF VASCULAR CONDITIONS
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2005016286A8 (en) Pyrazine modulators of cannabinoid receptors
PH12011501683A1 (en) Helix 12 directed non-steroidal antiandrogens
CL2007002953A1 (en) COMPOUNDS DERIVED FROM ESPIRO-OXINDOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF PAIN, CANCER, PRURITE, BENIGN PROSTATIC HYPERPLASIA, HYPERCHOLESTEROLEMIA.
ECSP024382A (en) SERINA PROTEASE INHIBITORS
WO2003045494A3 (en) Imiquimod therapies
DE60334536D1 (en) FURYLVERBINDUNGEN
CA2334460A1 (en) Pharmaceutical compositions comprising alpha-adrenoceptor antagonists and muscarinic antagonists
WO2005049000A3 (en) Treatment of phenylketonurias with bh4
NZ535531A (en) Compound and use in treatment
NZ547565A (en) Substituted arylpyrazoles as parasiticidal agents
AP2002002427A0 (en) Ppar compounds.
AU9678501A (en) Pharmaceutical solutions of modafinil compounds
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
PE20040596A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A LIPASE AND GLUCOMANAN INHIBITOR
GB0326633D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)